SCHEMBL2495523

SCHEMBL2495523

O=C(CCCN1C(=O)C=CC1=O)OC(=O)CCCN1C(=O)C=CC1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 8/20 0.58
FAAH O00519 5/20 0.58
PTGS1 P23219 7/20 0.56
PTGS2 P35354 7/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
HSP90AA1 P07900 1/20 0.56
TLR9 Q9NR96 1/20 0.56
LMNA P02545 1/20 0.56
TP53 P04637 1/20 0.56
MAPT P10636 1/20 0.56
PKM P14618 1/20 0.56
XBP1 P17861 1/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
GPR35 Q9HC97 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499154 0.92 PTGS1 (0.68) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL28668492 0.91 PTGS1 (0.56) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL28038312 0.91 PTGS1 (0.66) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL9734294 0.88 PTGS1 (0.46) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL1230250 0.88 ALDH1A1 (0.52) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL16579831 0.86 PTGS1 (0.60) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL4618418 0.86 ALDH1A1 (0.50) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL22372519 0.85 PTGS1 (0.73) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL8197865 0.85 PTGS1 (0.69) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL5161619 0.85 MGLL (0.54) MGLLFAAHPTGS1PTGS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2023-02-07 US disclosed
CN-108368143-B Monomaleimide functionalized platinum compounds for cancer therapy 维也纳医科大学 2022-02-01 CN disclosed
US-8029979-B2 Method for determining the substrate specificity of an enzyme JPT PEPTIDE TECHNOLOGIES GMBH (DE) 2011-10-04 US disclosed
US-20060234308-A1 Method for determining the substrate specificity of an enzymatic activity and a device therefor JERINI AG (DE) 2006-10-19 US disclosed
US-20040171097-A1 Method for determining the substrate specificity of an enzymatic activity and a device therefor JERINI AG (DE) 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy FOLR2, FOLR1, SLC19A1 MGLL 3581/4885FAAH 3461/4885PTGS1 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.